BMS-754807

Catalog No.S1124

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Cited by 12 Publications

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):619-630

PubMed: 30956007 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

Drug Deliv, 2018, 25(1):241-255

PubMed: 29334272 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29099049 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

1 Customer Review

Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	NYfZbmhiU2mwYYPlJIF{e2G7			MV3pcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS\|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR\|UxKD1iMUPuUUk>	M3PsU\|E6Pzd6MEK0
IGF-Sal	M3TyfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7			MVPJR\|UxRTdibl2=	NF;HeZIyQTd5OECyOC=>
CCRF-CEM (ALL)	NID0bWRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUP+OUDPxE1?	M2W4[2ROW09?	NVW3cJk3UUN3ME2xMlI{QSEQvF2=	NEHCXmwyQTl7NkK3Ni=>
PC3	M1GzeWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmH5glUh\|ryP	NFnm[pRFVVOR	MmjOTWM2OD1yLkm2OUDPxE1?	M{S5R\|E6QTl4Mkey
JD	NIriWVNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXH+OUDPxE1?	M2\C[WROW09?	MYrJR\|UxRTBwM{mxJO69VQ>?	MXGxPVk6PjJ5Mh?=
DU145	MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUfiSJB2hjVizszN	NGTOeG9FVVOR	M3;WfWlEPTB;MT60OlUh\|ryP	NHPJOokyQTl7NkK3Ni=>
KAG	NInycYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{HrVp42KM7:TR?=	MY\EUXNQ	NVf2OmNYUUN3ME2xMlY3PSEQvF2=	MVixPVk6PjJ5Mh?=
K-562 (CML)	NV3YZY5yT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXn+OUDPxE1?	NVj6bml[TE2VTx?=	M3;QdGlEPTB;Mj6zNFIh\|ryP	M{P3fVE6QTl4Mkey
B6-P210 (Murine ALL)	MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEfYXpZ,PSEQvF2=	M3LVTGROW09?	NHuxU41KSzVyPUGuNlk{KM7:TR?=	MVixPVk6PjJ5Mh?=
LN CAP-FGC	M3XrUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnLpglUh\|ryP	Mn62SG1UVw>?	NGnGXVFKSzVyPUGuOFM1KM7:TR?=	Mm\pNVk6QTZ{N{K=
VW	NXf3UXN6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHja[VF,PSEQvF2=	MmrxSG1UVw>?	NYnDWGozUUN3ME2wMlAyQSEQvF2=	NHH6eIkyQTl7NkK3Ni=>
MV411 (B Myelomonocytic)	M4\FOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3\LR542KM7:TR?=	MV3EUXNQ	NHrC[Y5KSzVyPUCuN\|Mh\|ryP	MU[xPVk6PjJ5Mh?=
MDA-PCa-2b	M1X6fWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmT5glUh\|ryP	MV;EUXNQ	NFTlblFKSzVyPUCuNFk5KM7:TR?=	MXuxPVk6PjJ5Mh?=
LG	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVfWUINNhjVizszN	NH:1b45FVVOR	MVjJR\|UxRTBwMEO4JO69VQ>?	MmHUNVk6QTZ{N{K=
RS411 (B cell precursor-ALL)	MoXCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX\ublc1hjVizszN	NHHUdnBFVVOR	NHW2eHpKSzVyPUCuNVAzKM7:TR?=	NXL5XlJVOTl7OU[yO\|I>
22-r-1	MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVy2VYhnhjVizszN	MkK5SG1UVw>?	MkL2TWM2OD1yLkG3OUDPxE1?	MYSxPVk6PjJ5Mh?=
5838	MnLPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NH3XfWV,PSEQvF2=	M{P4RmROW09?	NE\l[ZhKSzVyPUCuNFM1KM7:TR?=	NX\KTnRkOTl7OU[yO\|I>
P388 (Murine)	M2[3NGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXLhR\|N6hjVizszN	Mlf2SG1UVw>?	NWHNb4VDUUN3ME20MlI4KM7:TR?=	MYCxPVk6PjJ5Mh?=
A2780/S	NIfsTFZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3ixWJ42KM7:TR?=	M2Hm[mROW09?	M4j5cmlEPTB;MD6xNlIh\|ryP	MXexPVk6PjJ5Mh?=
RDES	NYDE[49lT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEPxS4J,PSEQvF2=	MlLaSG1UVw>?	MWLJR\|UxRTBwMEGyJO69VQ>?	NXex[XdTOTl7OU[yO\|I>
B6-T315I (Murine B-ALL)	MkXUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFXyd5R,PSEQvF2=	NXy4Opc{TE2VTx?=	NHLnVVNKSzVyPUKuPFMh\|ryP	MX:xPVk6PjJ5Mh?=
TOV 112D	NYXn[\|lKT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHzzTpJ,PSEQvF2=	NELENZFFVVOR	Ml7qTWM2OD1{LkG0OkDPxE1?	M3nXOVE6QTl4Mkey
TC32	NXPtOYhsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUjEXVRXhjVizszN	NHnxcXNFVVOR	MnvUTWM2OD1yLkCwPEDPxE1?	NVnTSXExOTl7OU[yO\|I>
HL60 (acute myelocytic)	MkfhS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MknzglUh\|ryP	NHGzZ29FVVOR	MlPhTWM2OD1yLkGyJO69VQ>?	M4LXc\|E6QTl4Mkey
TOV 21G	M37uVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGDh[lh,PSEQvF2=	MnToSG1UVw>?	MmnUTWM2OD12LkK3PUDPxE1?	M1ztclE6QTl4Mkey
TC71	M134emdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVT+OUDPxE1?	MoLRSG1UVw>?	NGrvZ5BKSzVyPUCuNFE1KM7:TR?=	MnTpNVk6QTZ{N{K=
HPN-ALL (T-cell)	NXPtTHdPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NE\lbZJ,PSEQvF2=	NHm4WYpFVVOR	MYjJR\|UxRTBwNUKg{txO	M37nPFE6QTl4Mkey
A2780R	MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnW4glUh\|ryP	NE\z[m5FVVOR	MV7JR\|UxRTFwNU[0JO69VQ>?	MlnMNVk6QTZ{N{K=
Rh1	NVL4O2tDT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkfzglUh\|ryP	NYDERZBITE2VTx?=	NYPHbZhzUUN3ME2wMlAzPyEQvF2=	MXGxPVk6PjJ5Mh?=
Kasumi-1 (acute myeloid)	M4jlXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NEHvbIN,PSEQvF2=	MX7EUXNQ	NWHBeZdTUUN3ME2wMlE3KM7:TR?=	NG\2ZZAyQTl7NkK3Ni=>
sk-ov-3	M3nKS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXf+OUDPxE1?	M1fZRWROW09?	Ml3CTWM2OD13LkGg{txO	NH\aNnEyQTl7NkK3Ni=>
ME	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoOwglUh\|ryP	MW\EUXNQ	Mn;6TWM2OD1yLkCxOUDPxE1?	Mn3SNVk6QTZ{N{K=
L1210 (Murine lymphocytic)	NInuVFNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYXrS4Z5hjVizszN	NFX6b4tFVVOR	M2\xVWlEPTB;Mj6zPUDPxE1?	NHrXZ5QyQTl7NkK3Ni=>
sw-626	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mnj2glUh\|ryP	MVPEUXNQ	MYjJR\|UxRTJwM{C2JO69VQ>?	MmHhNVk6QTZ{N{K=
CTR	NFrEVWdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXG4WHRqhjVizszN	MmTHSG1UVw>?	NEnCdo5KSzVyPUCuNlU{KM7:TR?=	MkLvNVk6QTZ{N{K=
ML2 (Myelomonocytic)	Mme0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NInkfYJ,PSEQvF2=	NFLJXmZFVVOR	NGTpflVKSzVyPUCuNFkh\|ryP	MlqxNVk6QTZ{N{K=
ovcar-3	NXj3[XhrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXf+OUDPxE1?	M2frdGROW09?	MmezTWM2OD13IN88US=>	M4DmOVE6QTl4Mkey
Rh36	MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYL+OUDPxE1?	NFzGbGFFVVOR	NXTZSW5WUUN3ME2xMlQ{OiEQvF2=	MVGxPVk6PjJ5Mh?=
MOLM-13 (acute myeloid)	NGTUN\|lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVP+OUDPxE1?	M4TjPGROW09?	M2HkVGlEPTB;MD60NkDPxE1?	NFTRfHcyQTl7NkK3Ni=>
ovcar-4	NUDORnVpT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NX7BSolZhjVizszN	NF3SPG1FVVOR	MWTJR\|UxRTFizszN	M3nDelE6QTl4Mkey
Rh41	M3LqOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWnONW57hjVizszN	M4rESGROW09?	MUnJR\|UxRTBwMEC1JO69VQ>?	Mnm1NVk6QTZ{N{K=
Mutz 2 (acute myeloid)	NFqyc\|NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmjKglUh\|ryP	MU\EUXNQ	NHuyN5pKSzVyPUGuNVUh\|ryP	M3HqV\|E6QTl4Mkey
ovcar-5	NYm5b5ZET3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXroSJBOhjVizszN	MWrEUXNQ	M{nESGlEPTB;MD6wOUDPxE1?	M{jGV\|E6QTl4Mkey
RD1	MoLvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUn+OUDPxE1?	NGD4S4NFVVOR	NGj1NYhKSzVyPUCuNFY5KM7:TR?=	NUfxPHFTOTl7OU[yO\|I>
OCI-AML 2 (acute myeloid)	NVLROoJFT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnW3glUh\|ryP	NVv3cGM2TE2VTx?=	MlmxTWM2OD1\|LkOzJO69VQ>?	MmnBNVk6QTZ{N{K=
786-O	Mni1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHe4Wpd,PSEQvF2=	MoPrSG1UVw>?	M1\UbmlEPTB;MT62OFch\|ryP	Mm\ONVk6QTZ{N{K=
A673	NHPiU2VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2L4cZ42KM7:TR?=	NHPQb5JFVVOR	MojoTWM2OD1yLkSwPEDPxE1?	NYi0cmwxOTl7OU[yO\|I>
TALL-1 (T-cell)	MkXFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2mxS542KM7:TR?=	MoPKSG1UVw>?	MVfJR\|UxRTFwMkig{txO	NUHFTGhvOTl7OU[yO\|I>
151-B	MmfOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVzmOXR5hjVizszN	NV3IT\|NjTE2VTx?=	M1HLUWlEPTB;Mj62O{DPxE1?	NEP0SHUyQTl7NkK3Ni=>
PFSK-1	MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NF61dFB,PSEQvF2=	MYLEUXNQ	M2HXbWlEPTB;MD6xN\|Ih\|ryP	MmLCNVk6QTZ{N{K=
THP-1	M1HU[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NV;aW5BqhjVizszN	MUXEUXNQ	MmPNTWM2OD14LkW4JO69VQ>?	NG\2bGEyQTl7NkK3Ni=>
HEK293	NGXjSXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NITM[mh,PSEQvF2=	MoG2SG1UVw>?	MXfJR\|UxRTBwOUG1JO69VQ>?	NVfpUG9iOTl7OU[yO\|I>
DAOY	MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVf+OUDPxE1?	MU\EUXNQ	MmHxTWM2OD1zLkm3PUDPxE1?	M3;NTlE6QTl4Mkey
SET2	NH3IUXlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXrN[HdLhjVizszN	NXziNpQyTE2VTx?=	NWPw[Xl3UUN3ME2wMlI6QCEQvF2=	M321RlE6QTl4Mkey
HTB-46	NHHBWpVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NELaU4x,PSEQvF2=	MU\EUXNQ	M3TuTWlEPTB;NT6yOUDPxE1?	MnTCNVk6QTZ{N{K=
SK-NAS	NX[wPGhwT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUX+OUDPxE1?	M2DRO2ROW09?	M2q5cGlEPTB;MD60PVch\|ryP	MUexPVk6PjJ5Mh?=
CTLL2	M13NTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2nIdp42KM7:TR?=	MnLkSG1UVw>?	M3XocWlEPTB-MT6wNEDPxE1?	M1m0NlE6QTl4Mkey
HTB-47	NVXRcYZJT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVnaOpZuhjVizszN	M171ZmROW09?	MlroTWM2OD1{LkC1OkDPxE1?	MWKxPVk6PjJ5Mh?=
LAN-1	MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVX+OUDPxE1?	MYnEUXNQ	M1jvPGlEPTB;MD6wOEDPxE1?	MWixPVk6PjJ5Mh?=
ST486	MoHrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYn1eWU5hjVizszN	NIXHbVZFVVOR	NVvWeYRSUUN3ME2xMlE6KM7:TR?=	M2LhPFE6QTl4Mkey
HS766T	NHznbnpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXf+OUDPxE1?	NHHzdZJFVVOR	NHm2VVdKSzVyPUKuNFAyKM7:TR?=	M2fqPVE6QTl4Mkey
IMR-32	MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NG\Y[2p,PSEQvF2=	MULEUXNQ	MWrJR\|UxRTBwMk[xJO69VQ>?	NGq1XWQyQTl7NkK3Ni=>
Daudi (Burkitt's)	MlztS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIO0cHR,PSEQvF2=	NFu4UIZFVVOR	NGHz[pdKSzVyPUKuOlM4KM7:TR?=	M3[yRVE6QTl4Mkey
Aspc-1	NYnQSGk3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYfwXY8zhjVizszN	M4TvTWROW09?	M4rWZmlEPTB;MD6zO\|kh\|ryP	NFXke5gyQTl7NkK3Ni=>
SK-NSH	NX7WZZRuT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWD+OUDPxE1?	MXnEUXNQ	NGXISYdKSzVyPUCuNVM6KM7:TR?=	NYKwSZRVOTl7OU[yO\|I>
MEC-1 (Chronic B cell)	NFHRNHhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVvkbpdHhjVizszN	MULEUXNQ	M{LNV2lEPTB;Mj62N\|ch\|ryP	MnjrNVk6QTZ{N{K=
Capan-2	NIPEb4VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NV61Tmk{hjVizszN	M1jJfWROW09?	MofOTWM2OD1zLke3OEDPxE1?	MlLTNVk6QTZ{N{K=
SHSY5Y	M3OzNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnrTglUh\|ryP	MYrEUXNQ	NV3ncnI3UUN3ME2wMlExPiEQvF2=	NW\4SVVOOTl7OU[yO\|I>
U937 (Histioocytic)	M1K1XWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{nVPJ42KM7:TR?=	MVvEUXNQ	NHr0PIFKSzVyPkWuNFAh\|ryP	MYmxPVk6PjJ5Mh?=
Bxpc-1	M{Xwd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH\oeZB,PSEQvF2=	Moe5SG1UVw>?	NFr3cnBKSzVyPUGuPVI1KM7:TR?=	M4jT[FE6QTl4Mkey
Bxpc-3	M4i4dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGLmTG9,PSEQvF2=	MV7EUXNQ	MoCxTWM2OD53LkCwJO69VQ>?	M3zaZlE6QTl4Mkey
HTB-92	M3zTd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVTB[YxOhjVizszN	NEixZ3JFVVOR	MnHTTWM2OD1zLkCyJO69VQ>?	Ml3SNVk6QTZ{N{K=
OCI-LY10 (B-cell)	NWe1Z294T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4P0dp42KM7:TR?=	MlmySG1UVw>?	NYHQNIZoUUN3ME2wMlQ2KM7:TR?=	NFXkRnEyQTl7NkK3Ni=>
PANC-1	NG\hfI5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYTLW4RJhjVizszN	MlX4SG1UVw>?	NHfFc2xKSzVyPkWuNFAh\|ryP	NIL3O20yQTl7NkK3Ni=>
To184.T	MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MljlglUh\|ryP	NGm1XGRFVVOR	NGnwRnRKSzVyPUCuOFY6KM7:TR?=	NGXMXVUyQTl7NkK3Ni=>
OCI-LY19 (B-cell)	Mn3VS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUH+OUDPxE1?	M4XLW2ROW09?	NHXSSWZKSzVyPUCuOEDPxE1?	MnHINVk6QTZ{N{K=
PANC-1 BM	M3rhXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml7kglUh\|ryP	NVPR[W5nTE2VTx?=	MmD3TWM2OD53LkCwJO69VQ>?	M4HTclE6QTl4Mkey
SA-4	NVK3[IFkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVfOOVRMhjVizszN	NGPISXVFVVOR	MmP6TWM2OD1zLkOwNUDPxE1?	MmjwNVk6QTZ{N{K=
RPMI 8226	NWTD[lN5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYKxVmpRhjVizszN	MYrEUXNQ	MkC0TWM2OD1zLkK5N{DPxE1?	NVPVPI5uOTl7OU[yO\|I>
HPAF-II	MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIjBPIh,PSEQvF2=	MoXrSG1UVw>?	NHHrbYRKSzVyPUCuOlQ1KM7:TR?=	MlfnNVk6QTZ{N{K=
SHP-77	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnvQglUh\|ryP	NGjsRmZFVVOR	NH;iNlNKSzVyPUGuPFg5KM7:TR?=	Mlu3NVk6QTZ{N{K=
U266 B1	MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXfsR2FQhjVizszN	MXLEUXNQ	MUfJR\|UxRTFwNk[5JO69VQ>?	MV6xPVk6PjJ5Mh?=
Hs700t	M{LYWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1PrWJ42KM7:TR?=	NX\0NY1NTE2VTx?=	NVnDfXpFUUN3ME2wMlI{OSEQvF2=	MUexPVk6PjJ5Mh?=
NCI-446	NUP1e2EyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVL4fXYzhjVizszN	NIjLXZlFVVOR	NH\lZZhKSzVyPUGuNVU1KM7:TR?=	NFnsVYEyQTl7NkK3Ni=>
H929	M33ENWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmTKglUh\|ryP	MYTEUXNQ	MUfJR\|UxRTBwMEG0JO69VQ>?	M3v4fFE6QTl4Mkey
PL45	NYG1fVAyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4XyRp42KM7:TR?=	NFL3[YZFVVOR	MlTkTWM2OD1{LkK1OUDPxE1?	Mnr4NVk6QTZ{N{K=
NCI-H383	NYfRVmVpT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVnUfFlbhjVizszN	NX63XVc1TE2VTx?=	NH3uUZVKSzVyPkWuNFAh\|ryP	Mm\SNVk6QTZ{N{K=
JJN3	MkDiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4jtZp42KM7:TR?=	NXr6bnRjTE2VTx?=	MXLJR\|UxRTJwNEOzJO69VQ>?	NFvPTVMyQTl7NkK3Ni=>
SU.86.86	NVTkO21VT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWH+OUDPxE1?	NX;sS246TE2VTx?=	MmnpTWM2OD1{Lk[3NkDPxE1?	NHi1cVEyQTl7NkK3Ni=>
H1299	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVjpO\|JyhjVizszN	MV\EUXNQ	NV3ucllFUUN3ME61MlAxKM7:TR?=	MoO1NVk6QTZ{N{K=
MDA-MB-468	NIDibW5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYXsWXB5hjVizszN	NWn6TJU1TE2VTx?=	MoXNTWM2OD1yLkWwOEDPxE1?	M4Phd\|E6QTl4Mkey
SW1990	MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYDGWnJqhjVizszN	MWLEUXNQ	MWXJR\|UxRTBwOEK2JO69VQ>?	NX\xVYVCOTl7OU[yO\|I>
Calu-6	M{jyfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWj0bHRrhjVizszN	MkDQSG1UVw>?	NF7LZVRKSzVyPkWuNFAh\|ryP	MkPlNVk6QTZ{N{K=
MDA-MB-231	NWft[mllT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEDOVJh,PSEQvF2=	NIfE[IhFVVOR	Mnf1TWM2OD1zLk[0PEDPxE1?	NWrJNIt4OTl7OU[yO\|I>
SW-684	M1XUN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVz+OUDPxE1?	NXvPcFc2TE2VTx?=	NV;4dZl5UUN3ME61MlAxKM7:TR?=	M2S5SlE6QTl4Mkey
H209	Ml;CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXH+OUDPxE1?	NHrmb4lFVVOR	NXr3TVFkUUN3ME2xMlE6OyEQvF2=	M1v3[lE6QTl4Mkey
MDA-MB-231T	MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYDtPJZthjVizszN	NHXqV\|JFVVOR	NFTPR4ZKSzVyPkWuNFAh\|ryP	MXWxPVk6PjJ5Mh?=
HT1080/S	MnHxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MkTlglUh\|ryP	NInMeHhFVVOR	MXvJR\|UxRTBwNUOxJO69VQ>?	NWPyOVkzOTl7OU[yO\|I>
H526 0.044	M{DHXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{HKNJ42KM7:TR?=	MV7EUXNQ	NHru[m1KSzVyPUCuNFQ1KM7:TR?=	NXPqWJZ6OTl7OU[yO\|I>
DU4475 2.431	NGCzboZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUP+OUDPxE1?	M3ThPWROW09?	MlPrTWM2OD1{LkSzNUDPxE1?	NYLjbGQyOTl7OU[yO\|I>
HCT116	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYLHeWpChjVizszN	MULEUXNQ	NF;t[nhKSzVyPUCuPFUzKM7:TR?=	M2fvU\|E6QTl4Mkey
M109	MnWzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGPSWnp,PSEQvF2=	MkLWSG1UVw>?	MYHJR\|UxRTFwMEW1JO69VQ>?	MYixPVk6PjJ5Mh?=
BT549	M1vwNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2fmep42KM7:TR?=	MmDHSG1UVw>?	Mlz3TWM2OD1zLk[0OUDPxE1?	NXjORmdIOTl7OU[yO\|I>
HCT116/VM46	MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGLzT4Z,PSEQvF2=	MnnvSG1UVw>?	NWrkUlYzUUN3ME2xMlcxOiEQvF2=	M3XnTVE6QTl4Mkey
H460	NFjTW4VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{DYXp42KM7:TR?=	NX;EcFM2TE2VTx?=	MUTJR\|UxRTBwN{m1JO69VQ>?	NEnKO4wyQTl7NkK3Ni=>
MCF-7	MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFzHbJZ,PSEQvF2=	M3v6NGROW09?	M4DyOmlEPTB;MD6wNVYh\|ryP	M{DHSFE6QTl4Mkey
GEO	NEWwOWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIHGO2R,PSEQvF2=	NHf2NXJFVVOR	NWjhSm9{UUN3ME2wMlM2PiEQvF2=	MUexPVk6PjJ5Mh?=
H441 0.646	M3HvVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWfGelRlhjVizszN	MYTEUXNQ	M1XQTGlEPTB;MD62OFYh\|ryP	NGPSNHMyQTl7NkK3Ni=>
MCF-7-807R	NUHWfIN5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUnubpNMhjVizszN	NFm0fJhFVVOR	M3rhZ2lEPTB;MD60PUDPxE1?	NFrPWWsyQTl7NkK3Ni=>
Colo205	MoTXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NH65bmV,PSEQvF2=	M3vC[WROW09?	MWHJR\|UxRTBwMUC0JO69VQ>?	M3;SNFE6QTl4Mkey
H292	Mne0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWL4cW1qhjVizszN	NGXCU5JFVVOR	NYqwUo9yUUN3ME2wMlc5QCEQvF2=	NIroVJkyQTl7NkK3Ni=>
BT474 (S)	NYrieFVGT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHPLeo1,PSEQvF2=	NUPHempWTE2VTx?=	NFftdXBKSzVyPUKuOFA{KM7:TR?=	NUjw[3RyOTl7OU[yO\|I>
HT-29	NH7pNHRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NW\ieW16hjVizszN	M1:2SWROW09?	NFf3b4ZKSzVyPUKuNVA{KM7:TR?=	M1fHPVE6QTl4Mkey
A549	MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnHJglUh\|ryP	MnLuSG1UVw>?	NFXYR3RKSzVyPUCuOlc2KM7:TR?=	MXSxPVk6PjJ5Mh?=
BT474-M1	M1HtZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVL+OUDPxE1?	MnPJSG1UVw>?	M1zNc2lEPTB;Mj6zOlUh\|ryP	MYCxPVk6PjJ5Mh?=
SW480	M{DZcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXn+OUDPxE1?	NFj4NIJFVVOR	MmDGTWM2OD53LkCwJO69VQ>?	MoTqNVk6QTZ{N{K=
L2987	NED3Um1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mn\DglUh\|ryP	NVz5dot{TE2VTx?=	MWTJR\|UxRTBwNESyJO69VQ>?	NUjSW2t1OTl7OU[yO\|I>
AU565	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{n1SJ42KM7:TR?=	NHfEdYdFVVOR	MYPJR\|UxRTRwOUeg{txO	MU[xPVk6PjJ5Mh?=
SW403	MmLWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MV;+OUDPxE1?	MoD6SG1UVw>?	NFvuWJJKSzVyPUCuNlIh\|ryP	NXXTUIkzOTl7OU[yO\|I>
H1437	MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmfYglUh\|ryP	Ml3RSG1UVw>?	MW\JR\|UxRTBwNUKzJO69VQ>?	NX3EWmNTOTl7OU[yO\|I>
BT-20	MmXCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmL0glUh\|ryP	NXz0V4lXTE2VTx?=	M{jiRmlEPTB;Mz61OlIh\|ryP	MX6xPVk6PjJ5Mh?=
Colo320HSR	MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1vXR542KM7:TR?=	NEfLO4pFVVOR	NV;pbWplUUN3ME2wMlAyOSEQvF2=	MVWxPVk6PjJ5Mh?=
H2087	M3TOOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUn+OUDPxE1?	NXG1UXR3TE2VTx?=	MYHJR\|UxRjFwMECg{txO	M{DtNVE6QTl4Mkey
HCC1419	MkPPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Ml7iglUh\|ryP	NIrtV4hFVVOR	NH\6c5FKSzVyPUKuOVE4KM7:TR?=	MWGxPVk6PjJ5Mh?=
WiDr	M2XKVmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVHNb2E2hjVizszN	MVjEUXNQ	MljjTWM2OD1yLkC3OkDPxE1?	MmX2NVk6QTZ{N{K=
H661 0.573	NInWSHhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXnpTlV1hjVizszN	M2PUZWROW09?	MWjJR\|UxRTBwNUezJO69VQ>?	M4jCN\|E6QTl4Mkey
HCC-38	MmrOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX3+OUDPxE1?	Ml7CSG1UVw>?	MULJR\|UxRjVwMECg{txO	NH;MdJkyQTl7NkK3Ni=>
LS174T	Moq4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmGxglUh\|ryP	M{e5fWROW09?	MoPlTWM2OD1yLkWzOUDPxE1?	NFrWUXoyQTl7NkK3Ni=>
H211	MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NI\YbJl,PSEQvF2=	NWPDPXBETE2VTx?=	M3uxTmlEPTB;MD63N\|Mh\|ryP	NEX3O3gyQTl7NkK3Ni=>
HCC70	MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkXFglUh\|ryP	MXzEUXNQ	Mn7VTWM2OD1zLkW1JO69VQ>?	NYX4[WhqOTl7OU[yO\|I>
SW116	MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWPsR3JrhjVizszN	MXzEUXNQ	NGDJTnZKSzVyPUCuNFY4KM7:TR?=	NVqy[5VmOTl7OU[yO\|I>
H513	NIXE[WNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3Pob542KM7:TR?=	NVrOZpZ2TE2VTx?=	M{jiRWlEPTB;ND60OFgh\|ryP	NH7mbpgyQTl7NkK3Ni=>
MDA-MB-157	M4Tkbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIrzfZJ,PSEQvF2=	NW\IWo94TE2VTx?=	M{fKNWlEPTB;MD6wN\|Yh\|ryP	NHmxU3EyQTl7NkK3Ni=>
H2052	MlS1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mm[wglUh\|ryP	M1fh[WROW09?	MkXZTWM2OD1zLkC1JO69VQ>?	MofTNVk6QTZ{N{K=
MDA-MB-415	NULL[2JPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXP+OUDPxE1?	M3XNUWROW09?	M1jDbmlEPTB-NT6wNEDPxE1?	M2jsNFE6QTl4Mkey
DLD-1	NHfEephIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoHVglUh\|ryP	NH7YdmlFVVOR	NUHhZW1UUUN3ME2wMlkxQSEQvF2=	Mme3NVk6QTZ{N{K=
H2595	NFK0WotIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2i4dZ42KM7:TR?=	NI\NXZVFVVOR	NWfGeHFHUUN3ME20MlQ4PSEQvF2=	MVSxPVk6PjJ5Mh?=
MDA-MB-435S	MmrmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M{C5Z542KM7:TR?=	NVPsT2pbTE2VTx?=	MnvhTWM2OD1zLki2PUDPxE1?	NVXRRZd{OTl7OU[yO\|I>
HCT15	MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYLx[2tLhjVizszN	M1Trd2ROW09?	MYTJR\|UxRjFwMECg{txO	NWDpenZUOTl7OU[yO\|I>
SK-Hep1	NUDGdoVkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYDpO5BXhjVizszN	M4LlUWROW09?	MoLITWM2OD1yLkG0OkDPxE1?	MYWxPVk6PjJ5Mh?=
MDA-MB-436	NHm5RVZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnrrglUh\|ryP	MoXOSG1UVw>?	NH:x[4lKSzVyPUWuOVAzKM7:TR?=	NVfEeYNHOTl7OU[yO\|I>
KM12C	NXLtTldJT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUn+OUDPxE1?	MX3EUXNQ	MW\JR\|UxRTBwMEW0JO69VQ>?	M2jCOlE6QTl4Mkey
HEPG2	NEnEUXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MX;+OUDPxE1?	M2nmOWROW09?	Mk\xTWM2OD1yLkCyOUDPxE1?	MnXHNVk6QTZ{N{K=
MDA-MB-453	NUjRPXJVT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWT+OUDPxE1?	MVfEUXNQ	MnjDTWM2OD1zLki2PUDPxE1?	NHjyNVAyQTl7NkK3Ni=>
KM12SM	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{HUVJ42KM7:TR?=	M3fwfGROW09?	NF[zcIpKSzVyPUCuNFU6KM7:TR?=	NULte25COTl7OU[yO\|I>
1483	NV;IVYt6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnrKglUh\|ryP	MmO3SG1UVw>?	NUe1ZXhTUUN3ME2yMlE6KM7:TR?=	MmLNNVk6QTZ{N{K=
Hs578t	M2Tw[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGL5N4R,PSEQvF2=	MV\EUXNQ	MUTJR\|UxRTFwMki3JO69VQ>?	NWDXNmhjOTl7OU[yO\|I>
LS180	Mn3CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3K2cp42KM7:TR?=	MoPHSG1UVw>?	MXrJR\|UxRTBwNkm2JO69VQ>?	NITnZXoyQTl7NkK3Ni=>
FaDu	NUnSWlJxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M33YPJ42KM7:TR?=	NITp[HFFVVOR	NIPIT2NKSzVyPUGuNlch\|ryP	NHPzToIyQTl7NkK3Ni=>
ZR-75-1	NIT5fJBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmXtglUh\|ryP	NGS4T\|lFVVOR	NVu5SVBIUUN3ME2yMlA5PCEQvF2=	NVTQRmh1OTl7OU[yO\|I>
LS513	NGrMelVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlzJglUh\|ryP	M130ZWROW09?	Mk\lTWM2OD1yLkGzOUDPxE1?	NXvKbVg2OTl7OU[yO\|I>
Detroit.562	MlTyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFT3[ZJ,PSEQvF2=	NWfCXFhGTE2VTx?=	MWrJR\|UxRTFwMUSg{txO	NFLQd4cyQTl7NkK3Ni=>
ZR-75-30	Mn\1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NV;wdWxqhjVizszN	MW\EUXNQ	MV3JR\|UxRjVwMECg{txO	MlnvNVk6QTZ{N{K=
RKO-PM	Moj0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NY\4SpVmhjVizszN	NETFe\|BFVVOR	NYrQV5dDUUN3ME2wMlI{OiEQvF2=	NXzOV5c6OTl7OU[yO\|I>
Cal.27	MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1TkUZ42KM7:TR?=	NWG5[\|lCTE2VTx?=	M1;w[GlEPTB;MjFOwG0>	M1;ze\|E6QTl4Mkey
KPL4	M2rQ[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWjtUlVQhjVizszN	M{TuS2ROW09?	MUXJR\|UxRTFwMkWyJO69VQ>?	NITZZoIyQTl7NkK3Ni=>
PKO-RM13	MlLuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUPBdWlEhjVizszN	MlrjSG1UVw>?	MXjJR\|UxRTBwNEK1JO69VQ>?	MmjKNVk6QTZ{N{K=
HS.53.T	MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXj+OUDPxE1?	MkP6SG1UVw>?	MVTJR\|UxRTBwN{mg{txO	MnTaNVk6QTZ{N{K=
EMT6	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIDzU3V,PSEQvF2=	NWi0Tod7TE2VTx?=	NIrSV2FKSzVyPUCuPFA3KM7:TR?=	MnntNVk6QTZ{N{K=
SNU-C1	MmTOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NILy[3J,PSEQvF2=	MnfTSG1UVw>?	NWnCWlA4UUN3ME2wMlAxPyEQvF2=	M{nHTFE6QTl4Mkey
SQCCY1	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2DRZZ42KM7:TR?=	MoP3SG1UVw>?	MYnJR\|UxRTBwN{mg{txO	NFXGXYoyQTl7NkK3Ni=>
SW480	M1y1dWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mkj4glUh\|ryP	MmDmSG1UVw>?	M{fHWWlEPTB;MD6wN\|ch\|ryP	MoLRNVk6QTZ{N{K=
SCC9	NYHSNo1jT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXXWfFdohjVizszN	MWPEUXNQ	NVjx[Gt3UUN3ME2wMlc2KM7:TR?=	M{ixPFE6QTl4Mkey
SK-LMS-1	NInIfmNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1nUZZ42KM7:TR?=	MkjUSG1UVw>?	NXr5eFgxUUN3ME2wMlY5PyEQvF2=	NHnafGoyQTl7NkK3Ni=>
SCC25	MmroS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NInDOHV,PSEQvF2=	MWPEUXNQ	NHrwOG9KSzVyPUCuOlgh\|ryP	MkjiNVk6QTZ{N{K=
U87	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4fnN542KM7:TR?=	MmTtSG1UVw>?	NGfYbJBKSzVyPUCuPVUh\|ryP	M{e2bFE6QTl4Mkey
SCC15	M3rDVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIrweHN,PSEQvF2=	MX\EUXNQ	M2\oT2lEPTB;MD62O{DPxE1?	MV6xPVk6PjJ5Mh?=
T98G	M3v0S2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MX;+OUDPxE1?	MlLKSG1UVw>?	MUnJR\|UxRTFwMkG4JO69VQ>?	NWS4UYNWOTl7OU[yO\|I>
SCC4	NFXjPY9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3S3UZ42KM7:TR?=	NYjpVoxoTE2VTx?=	MVLJR\|UxRTBwNkOg{txO	NFjyVo4yQTl7NkK3Ni=>
U118	NIPJUJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MofCglUh\|ryP	NFXUUG9FVVOR	NFTFbINKSzVyPUGuOlE5KM7:TR?=	MW[xPVk6PjJ5Mh?=
TU167	Ml\mS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYP+OUDPxE1?	NV\XbFVxTE2VTx?=	NIrIe2dKSzVyPUSuOVIh\|ryP	MmfrNVk6QTZ{N{K=
NCI-H727	MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3ezV54yOOLCit88US=>	NEL6dJpFVVOR	NXzJfGtmUUN3ME20Nlghdk1?	MlXTNlA{QDV5NEe=
NCI-H720	M4XwT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUjmV5BthjFy4pEK{txO	NV;OfmdQTE2VTx?=	MXrJR\|UxRTJwODFOwG0>	NI\KW\|gzODN6NUe0Oy=>
NCI-H835	MmTTS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4Pq[Z4yOOLCit88US=>	M{jKSmROW09?	NHT6PZhKSzVyPUGg{txO	MWKyNFM5PTd2Nx?=
NCI-H727	NXzRXnp4U2mwYYPlJIF{e2G7	MWL+NVDjiIsQvF2=	M2PvcmROW09?	NUTUR2xucW6qaXLpeJMh[2:wc4TpeJV1cX[nIFnHSlFTKGG3dH;wbI9{eGixconsZZRqd25?	NV63UplKOjB\|OEW3OFc>
RD	MmnXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3\aRp4yOOLCit88US=>		NXrwfHpvUUN3ME2xMlEzKML3TR?=	NUnIdlY2OjF{OUi3OFU>
Rh41	NILxUZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUL+NVDjiIsQvF2=		M{HPSGlEPTB;MD6wO{DDvU1?	MWSyNVI6QDd2NR?=
Rh18	NUnObFhwT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoPyglEx6oDMzszN		NISzU5FKSzVyPUSuPVYhyrWP	MojGNlEzQTh5NEW=
Rh30	NHXYU\|FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFe2UJp,OTEkgJtOwG0>		NWT2R251UUN3ME2wMlE6KML3TR?=	M3PrWFIyOjl6N{S1
BT-12	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{nZRZ4yOOLCit88US=>		M4rRZ2lEPTB;MD63PEDDvU1?	Mk\QNlEzQTh5NEW=
CHLA-266	Mk\OS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHLDSFB,OTEkgJtOwG0>		MoDtTWM2OD1yLki5JOK2VQ>?	M2XZTFIyOjl6N{S1
TC-71	NWnpZVk5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1nEdJ4yOOLCit88US=>		M1TacmlEPTB;MD6xNUDDvU1?	NXPSSnlPOjF{OUi3OFU>
CHLA-9	NWHpdGMxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVP+NVDjiIsQvF2=		MVLJR\|UxRTBwMUKgxtVO	NGnxd2wzOTJ7OEe0OS=>
CHLA-10	M3vuPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NI[zd4p,OTEkgJtOwG0>		MWfJR\|UxRTBwNkKgxtVO	MknINlEzQTh5NEW=
CHLA-258	M4TnV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYD1O\|FvhjFy4pEK{txO		NWnwRo9UUUN3ME2wMlI4KML3TR?=	NWDiNHppOjF{OUi3OFU>
GBM2	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGWycHd,OTEkgJtOwG0>		MojvTWM2OD1zLkS3JOK2VQ>?	M1nhflIyOjl6N{S1
NB-1643	MoflS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUT+NVDjiIsQvF2=		MlXjTWM2OD1yLkGyJOK2VQ>?	M{LRTlIyOjl6N{S1
NB-EBc1	NH7YN2dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUjuTlZShjFy4pEK{txO		NHTVeWZKSzVyPUCuN\|UhyrWP	MofMNlEzQTh5NEW=
CHLA-90	MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NHLpXoR,OTEkgJtOwG0>		MXrJR\|UxRTBwN{egxtVO	MWeyNVI6QDd2NR?=
CHLA-136	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Moj5glEx6oDMzszN		NH7z[IpKSzVyPUCuOVIhyrWP	MXSyNVI6QDd2NR?=
NALM-6	M13aWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYf+NVDjiIsQvF2=		MWXJR\|UxRTBwNEmgxtVO	NHy5OXczOTJ7OEe0OS=>
COG-LL-317	M4Dnd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmfXglEx6oDMzszN		NGTnO2ZKSzVyPUGuN\|ghyrWP	NWPqW5FkOjF{OUi3OFU>
RS4;11	MlL2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHq1TFV,OTEkgJtOwG0>		Mk\KTWM2OD1yLkO4JOK2VQ>?	MXeyNVI6QDd2NR?=
MOLT-4	NWLiUYdtT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3TEfZ4yOOLCit88US=>		M{LifWlEPTB;MD61N{DDvU1?	M3rlSVIyOjl6N{S1
CCRF-CEM	M1XKd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUH+NVDjiIsQvF2=		M3r3d2lEPTB;MT6xN{DDvU1?	NYHt[VFQOjF{OUi3OFU>
Kasumi-1	NHruflFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4HNcp4yOOLCit88US=>		NHT3TWpKSzVyPUGuNkDDvU1?	NVrXZ3JKOjF{OUi3OFU>
Karpas-299	NFriSFZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlLjglEx6oDMzszN		MlO4TWM2OD1zLk[0JOK2VQ>?	MV2yNVI6QDd2NR?=
Ramos-RA1	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYH+NVDjiIsQvF2=		NXnIO3JOUUN3ME2xMlMyKML3TR?=	NH7lbWozOTJ7OEe0OS=>
Rh30	NGPzcHBHfW6ldHnvckBie3OjeR?=			M2[0XIlv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	NFnySlIzPTl{NUO3PC=>
Rh41	MXvGeY5kfGmxbjDhd5NigQ>?			NGG4boVqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:\|cHjvdplt[XSrb36=	M{\DbFI2QTJ3M{e4
RD	Ml3XSpVv[3Srb36gZZN{[Xl?			M2qxO4lv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	NVr6eoJiOjV7MkWzO\|g>
A549	NFeyZWlMcW6jc3WgZZN{[Xl?	MkTmNE426oDMzszN	M2nZPGROW09?	NG\URYpqdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>?	Mnm0NlY6Ojh3N{i=
NCI-H358	M4GzfGtqdmG\|ZTDhd5NigQ>?	NYLkUGR4OC534pEK{txO	NVLRPItUTE2VTx?=	Ml:xbY5pcWKrdIOgTWdHNUmUL1nSJIFkfGm4YYTpc44>	MWWyOlkzQDV5OB?=
A549	M{T6dmZ2dmO2aX;uJIF{e2G7	NYnRSJhOOC534pEK{txO	NH\0XoFFVVOR	MoLpZ4F2e2W\|IHGgZ49v[3W{cnXueEBl\WO{ZXHz[UBqdiCyaH;zdIhwenmuYYTl[EBCU1RiYX7kJGVTUw>?	Mlv4NlY6Ojh3N{i=
NCI-H358	MX3GeY5kfGmxbjDhd5NigQ>?	NWLZVYdjOC534pEK{txO	NYfFdo9DTE2VTx?=	NYL2fVdt[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?=	MXGyOlkzQDV5OB?=
A549	MlO1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX\Gb3A3hjFy4pEK{txO	NYTZPWp6TE2VTx?=	NFv0XVZKSzVyPUCuO\|Yh\|ryP	NGLiNpczPjl{OEW3PC=>
NCI-H358	M4jBXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUfMXWZlhjFy4pEK{txO	NX2wXFFITE2VTx?=	NYfYenBWUUN3ME2xMlA6KM7:TR?=	NX\wPG1WOjZ7Mki1O\|g>
A549	MWfBdI9xfG:\|aYOgZZN{[Xl?	M3PsblAvPeLCit88US=>	NV;Zell4TE2VTx?=	NXHjUmgycW6mdXPld{BCeG:ydH;zbZM>	M4q1OlI3QTJ6NUe4
NCI-H358	MlPxRZBweHSxc3nzJIF{e2G7	NHXjbmUxNjYkgJtOwG0>	NV3lWHJLTE2VTx?=	MnjhbY5lfWOnczDBdI9xfG:\|aYO=	MW[yOlkzQDV5OB?=
A549	MXPGeY5kfGmxbjDhd5NigQ>?	NHnybGExNjYkgJtOwG0>	M2[4RmROW09?	MWHy[YR2[2W\|IIfveY5lKGOub4P1doU>	NYPCVJZyOjZ7Mki1O\|g>
NCI-H358	NIHPTVdHfW6ldHnvckBie3OjeR?=	NXj2[\|JSOC534pEK{txO	MV3EUXNQ	NX;4b5VZemWmdXPld{B4d3WwZDDjcI9{fXKn	MW[yOlkzQDV5OB?=

... Click to View More Cell Line Experimental Data

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	+ Expand Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	+ Expand Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol) Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324|Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 12 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 12 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)